Watson to Match Patients to Clinical Trials

IBM’s cognitive computer will be individualizing trial plans for cancer patients at the Mayo Clinic.

Written byBob Grant
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, CLOCKREADYIBM’s Watson is one busy machine. Already deployed to aid researchers and clinicians at several institutions, the “cognitive computer” is now helping oncologists at the Mayo Clinic in Rochester, Minnesota, to sift through reams of patient records and sort individuals afflicted with cancer into appropriate clinical trials. “In an area like cancer, where time is of the essence, the speed and accuracy that Watson offers will allow us to develop an individualized treatment plan more efficiently so we can deliver exactly the care that the patient needs,” Steven Alberts, chair of medical oncology at Mayo Clinic, said in a statement.

Watson could ease the burden on clinical trial coordinators by matching thousands of patients, each with a unique health history and suite of symptoms, with thousands of experimental protocols that are designed to capture specific individuals. This should benefit not only patients, but the scientists who are running trials, said investigators at the Mayo Clinic. “With shorter times from initiation to completion of trials, our research teams will have the capacity for deeper, more complete investigations,” Nicholas LaRusso, a Mayo Clinic gastroenterologist and the project lead for the Mayo-IBM Watson collaboration, said in the statement. “Coupled with increased accuracy, we will be able to develop, refine and improve new and better techniques in medicine at a higher level.”

The computer, which will become more efficient ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies